Conv. Plasma
Nigella Sativa
Vitamin A
Vitamin C
Vitamin D

Home   COVID-19 treatment studies for Budesonide  COVID-19 treatment studies for Budesonide  C19 studies: Budesonide  Budesonide   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ramakrishnan (RCT) 82% 0.18 [0.04-0.79] hosp./ER 2/73 11/73 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 82% 0.18 [0.04-0.79] 2/73 11/73 82% improvement Yu (RCT) 39% 0.61 [0.22-1.67] death 6/787 10/799 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 39% 0.61 [0.22-1.67] 6/787 10/799 39% improvement Lee 33% 0.67 [0.42-1.08] cases 19/1,674 95/5,345 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 33% 0.67 [0.42-1.08] 19/1,674 95/5,345 33% improvement All studies 45% 0.55 [0.31-0.98] 27/2,534 116/6,217 45% improvement 3 budesonide COVID-19 studies Dec 7, 2021 Tau​2 = 0.08; I​2 = 27.1%; Z = 2.01 Effect extraction pre-specified Favors budesonide Favors control
Database of all budesonide COVID-19 studies. Submit updates/corrections.
Restrict:    All    Early    Late    Prophylaxis
Oct 27
Early Baker et al., medRxiv, doi:10.1101/2021.10.26.21265512 (Preprint) Dampening of the respiratory cytokine storm is promoted by inhaled budesonide in patients with early COVID-19
Details   Analysis of inflammatory mediators in the nasal mucosa of patients in the STOIC1 trial and a cohort of SARS-CoV-2 negative controls, showing that budesonide treatment decreased IL-33 and IFN-γ, implying a reduction in epithelial damage an..
Sep 9
PrEPPEP Lee et al., Research Square, doi:10.21203/ (Preprint)
cases, ↓32.6%, p=0.10
Association Between Inhaled Corticosteroid Use and the Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Nationwide Population-based Study in South Korea
Details   Retrospective 44,968 patients in South Korea, 7,019 on inhaled corticosteroids, showing no statistically significant differences in COVID-19 cases.
Aug 23
PrEPPEP Strauss et al., The Journal of Allergy and Clinical Immunology: In Practice, doi:10.1016/j.jaip.2021.08.007 (Peer Reviewed)
death, ↓23.5%, p=0.01
Intranasal Corticosteroids Are Associated with Better Outcomes in Coronavirus Disease 2019
Details   Retrospective 72,147 COVID-19+ patients in the USA, showing lower mortality, ICU admission, and hospitalization with intranasal corticosteroid use.
Jul 20
In Vitro Heinen et al., Viruses, doi:10.3390/v13071411 (Peer Reviewed) (In Vitro)
in vitro
Antiviral Effect of Budesonide against SARS-CoV-2
Details   In Vitro study showing dose-dependent inhibition of SARS-CoV-2 with budesonide.
May 5
In Vitro Konduri et al., bioRxiv, doi:10.1101/2021.05.05.442779 (Preprint) (In Vitro)
in vitro
ProLung™-budesonide Inhibits SARS-CoV-2 Replication and Reduces Lung Inflammation
Details   In Vitro study and animal study showing that ProLung™-budesonide inhibits SARS-CoV-2 replication (results for budesonide were not provided). ProLung™-budesonide and budesonide significantly decreased lung inflammation. ProLung™-budesonide..
Apr 12
Late Yu et al., The Lancet, doi:10.1016/S0140-6736(21)01744-X (preprint 4/12/21) (Peer Reviewed)
death, ↓39.1%, p=0.45
Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial
Details   Interim results from the PRINCIPLE trial, 1,073 treated with budesonide starting a median of 6 days after symptom onset, showing lower hospitalization/death, and faster recovery with treatment. ISRCTN86534580.
Mar 30
PrEPPEP Holt et al., medRxiv, doi:10.1101/2021.03.27.21254452 (Preprint)
cases, ↓36.0%, p=0.05
Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK)
Details   Prospective survey-based study with 15,227 people in the UK, showing lower risk of COVID-19 cases with vitamin A, vitamin D, zinc, selenium, probiotics, and inhaled corticosteroids; and higher risk with metformin and vitamin C. Statistica..
Feb 8
Early Ramakrishnan et al., Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00160-0 (preprint 2/8) (Peer Reviewed)
hosp./ER, ↓81.8%, p=0.02
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
Details   RCT with 73 budesonide patients and 73 control patients, showing significantly lower combined risk of an ER visit or hospitalization, and lower risk of no recovery at day 14.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.